Benzodiazepine receptor antagonism improves reaction time in latent hepatic encephalopathy

Psychopharmacology (Berl). 1995 Jun;119(3):295-8. doi: 10.1007/BF02246294.


Endogenous benzodiazepine-like substances are thought to play a role in the development of hepatic encephalopathy (HE). Ten patients with sub-clinical or latent hepatic encephalopathy (LHE) and ten normal controls were cognitively assessed pre- and post-infusion of 0.2 mg of the benzodiazepine (BZ) antagonist flumazenil in a placebo-controlled, cross-over, double-blind design. Flumazenil infusion resulted in a significant improvement in simple reaction time in patients, but not in controls. Saline infusion had no effect on any of the cognitive measures in either group. Flumazenil appeared to have a particular enhancing effect on the cognitive, as opposed to the motor, component of the reaction time task. This finding supports the view that the benzodiazepine/GABA system is implicated in the bradyphrenia that is characteristic of chronic liver disease, even before hepatic encephalopathy is apparent. We conclude that benzodiazepine receptor antagonism may improve cognitive function, particularly speed of information processing, in patients with latent hepatic encephalopathy.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Carrier Proteins / pharmacology
  • Cognition / drug effects*
  • Diazepam Binding Inhibitor
  • Female
  • Flumazenil / pharmacology*
  • GABA-A Receptor Antagonists*
  • Hepatic Encephalopathy
  • Humans
  • Male
  • Middle Aged
  • Reaction Time / drug effects*


  • Carrier Proteins
  • Diazepam Binding Inhibitor
  • GABA-A Receptor Antagonists
  • Flumazenil